Latest California Healthline Stories
Private equity-backed Headlands Research heralded its covid-19 vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.
Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
U.S. and global drug manufacturers invested in Russia’s sizable pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion. Not everyone agrees.
Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimer’s disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.
Health plans’ coverage of the medication, branded as Wegovy — which has a $1,300-a-month price tag — is not a sure thing.
When patients with common terminal illnesses such as cancer seek permission for compassionate use of therapies in the testing stage, their requests often are approved. But those with more unusual illnesses say drug companies are rarely willing to provide access.
If you or a loved one has COVID-19, here’s what to consider before seeking experimental treatments.
Muchos pacientes desconocen estas opciones o simplemente no pueden, o no saben, cómo acceder a ellas. Otros desconfían de los tratamientos no probados.
Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.